Drug Information

Drug (ID: DG00583) and It's Reported Resistant Information

• Name: Latanoprost
• Synonyms: Latanoprost; 130209-82-4; Xalatan; PhXA41; PHXA-41; PhXA 41; XA41; UNII-6Z5B6HVF6O; propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate; 6Z5B6HVF6O; Latanoprost, ethanol solution; latanoprost (isopropyl ester); CHEBI:6384; propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate; MFCD00216074; XA-41; T-2345; 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, 1-methylethyl ester, (5Z)-; isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate; Catioprost; (Z)-isopropyl 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate; SMR000466354; Xalatan (TN); latanoprostum; Nova-21027; Latanoprost [USAN:INN:BAN]; XA 41; PhXA34 [as 15(R,S)-isomer]; propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate; AR-202; L-PPDS; Latanoprost, (+/-)-; CHEMBL1051; SCHEMBL24698; MLS000759468; MLS001424106; Latanoprost (JAN/USP/INN); GTPL1961; DTXSID1041057; HMS2051H11; HMS2089J17; HMS3715N22; AMY30089; EX-A1770; HY-B0577; BDBM50240648; s4709; ZINC12468792; Latanoprost, >=98% (HPLC), oil; AKOS024458331; CCG-100946; DB00654; NC00196; NCGC00246969-01; NCGC00246969-06; (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptanoic acid 1-methylethyl ester; AS-75099; Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate; L0262; D00356; AB00640005-04; AB00640005-06; 209L824; A806039; Q634959; SR-01000759428; J-005764; SR-01000759428-4; UNII-8S5FB3XXG8 component GGXICVAJURFBLW-CEYXHVGTSA-N; Latanoprost, United States Pharmacopeia (USP) Reference Standard; Tris(2,4-dimethylphenyl)phosphine-5,5',5''''-trisulfonic acid trisodium salt; (1R,2R,3R,5S,3''R)-7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pentyl)-cyclopentyl]-hept-5-enoic acid isopropyl ester; (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoic acid propan-2-yl ester; 155551-81-8; 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl ester; 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl ester, (1R-(1-alpha(Z),2-beta(R*),3-alpha,5-alpha))-; Isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate; propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-bis(oxidanyl)-2-[(3R)-3-oxidanyl-5-phenyl-pentyl]cyclopentyl]hept-5-enoate
• Indication:
  In total 4 Indication(s)
  Glaucoma/ocular hypertension [ICD-11: 9C61]; Approved; [1]
  Glaucoma/ocular hypertension [ICD-11: 9C61]; Approved; [1]
  Ocular disease [ICD-11: 1F00]; Approved; [1]
  Open-angle glaucoma [ICD-11: 9C61]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Glaucoma [ICD-11: 9C61]; [1]
• Target: Prostaglandin F2-alpha receptor (PTGFR); PF2R_HUMAN; [1]
• Formula: C26H40O5
• IsoSMILES: CC(C)OC(=O)CCC/C=C\\C[C@H]1[C@H](C[C@H]([C@@H]1CC[C@H](CCC2=CC=CC=C2)O)O)O
• InChI: 1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1
• InChIKey: GGXICVAJURFBLW-CEYXHVGTSA-N
• PubChem CID: 5311221
• ChEBI ID: CHEBI:6384
• TTD Drug ID: D0C6NM
• DrugBank ID: DB00654

Type(s) of Resistant Mechanism of This Drug

  IDUE: Irregularity in Drug Uptake and Drug Efflux

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-09: Visual system diseases

Glaucoma [ICD-11: 9C61]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Irregularity in Drug Uptake and Drug Efflux (IDUE)

Key Molecule: ATP-binding cassette sub-family C5 (ABCC5) [1]

• Molecule Alteration: Expression; Regulation
• Resistant Disease: Glaucoma [ICD-11: 9C61.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: SIRC cells; Colon; Homo sapiens (Human); CVCL_2724
• In Vitro Model: SV40-HCEC cells; Kidney; Homo sapiens (Human); CVCL_1272
• Experiment for Molecule Alteration: RT-PCR; Immunoprecipitation assay; Western blot analysis; Immunostaining assay
• Experiment for Drug Resistance: Trypan blue exclusion test assay
• Mechanism Description: Taken together immunolocalization on human cornea, in vitro efflux in human, rabbit corneal and MRP5 over expressing cells, ex vivo and in vivo studies in intact rabbit cornea suggest that MRP5 on cornea can significantly lower the permeability of antiviral and glaucoma drugs.

Key Molecule: ATP-binding cassette sub-family C5 (ABCC5) [1]

• Molecule Alteration: Expression; Regulation
• Resistant Disease: Glaucoma [ICD-11: 9C61.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: SIRC cells; Colon; Homo sapiens (Human); CVCL_2724
• In Vitro Model: SV40-HCEC cells; Kidney; Homo sapiens (Human); CVCL_1272
• Experiment for Molecule Alteration: RT-PCR; Immunoprecipitation assay; Western blot analysis; Immunostaining assay
• Experiment for Drug Resistance: Trypan blue exclusion test assay
• Mechanism Description: Taken together immunolocalization on human cornea, in vitro efflux in human, rabbit corneal and MRP5 over expressing cells, ex vivo and in vivo studies in intact rabbit cornea suggest that MRP5 on cornea can significantly lower the permeability of antiviral and glaucoma drugs.

References

• Ref 1: Expression of multidrug resistance associated protein 5 (MRP5) on cornea and its role in drug efflux .J Ocul Pharmacol Ther. 2009 Apr;25(2):121-32. doi: 10.1089/jop.2008.0084. 10.1089/jop.2008.0084